31 may 2017
On may 30, 2017 approved by Nasdaq Stockholm noteringskommitté according to the usual terms to the trade of Saniona AB (publ) (“Saniona”) shares moved to the Nasdaq stock exchange and thus be delisted Saniona from Nasdaq First North Premier. The first day of trading on the main list are expected to be June 15, 2017, and the last day of trading on Nasdaq First North Premier will be on 14 June 2017. The share will be traded in the Small cap segment under the ticker “SANION”. Saniona retains the same ISIN code as the previous one, that is to say, SE0005794617. No new shares are issued in connection with the listing on Nasdaq Stockholm and Sanionas shareholders need not take any action in connection with this.
Saniona is listed on AktieTorget on april 22, 2014, and moved subsequently to the Nasdaq First North Premier on may 19, 2016.
Over the course of about a year, we have moved Saniona from being a research company to a company with several programs in the late clinical development phase. In parallel, we have also entered into several new collaborations with pharmaceutical companies. Saniona has today a broad and mature pipeline of internal and external läkemedelsprogram in collaboration with other pharmaceutical companies on indications with high medical needs where we believe we have good opportunities to create value for our shareholders, ” says Jørgen Drejer, CEO of Saniona.
A listing on Nasdaq Stockholm will create better conditions to broaden the aktieägarbasen and give the company access to the Swedish and international capital markets. The listing on Nasdaq Stockholm will also increase the knowledge of Saniona and our business among current and potential partners and suppliers.
A prospectus regarding the Sanionas listing on Nasdaq Stockholm will be published around the 12th of June 2017. The prospectus will be available on the Sanionas web, www.saniona.com.
Pareto Securities has been financial advisor and Setterwalls Advokatbyrå AB has served as legal advisor in connection with the listing.
For more information, please contact:
Thomas Feldthus, executive vice president and CFO, Saniona. Mobile: +45 2210 9957, E-mail: email@example.com
This information is such information that Saniona AB (publ) is obliged to publish under the EU marknadsmissbruksförordning. The information was submitted, by the above contact person in the government, for publication on 31 may 2017 there is a 12:30 CET.
Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and pain management. The company has an extensive portfolio of potential drug candidates in preclinical or clinical Phase. The research is focused on the ion channels that constitute a unique class that allows for and controls the passage of ions in cell membranes. The company has partnered with Boehringer Ingelheim GmbH. Proximagen Ltd., Productos the medix, S. A de S. V and Luc Therapeutics. Saniona is based in Copenhagen where the company has a forskningssite of high international class. Saniona is listed on Nasdaq First North Premier and has approximately 5,000 shareholders. Pareto Securities is the Certified Adviser of Saniona. The share is traded under the ticker SANION. Read more at www.saniona.com.
20170531 – PR – Listing to the Nasdaq Stockholm – ENG